Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PPHM
  • CUSIP:
Key Metrics:
  • Previous Close: $0.42
  • 50 Day Moving Average: $0.3777
  • 200 Day Moving Average: $0.3919
  • 52-Week Range: $0.29 - $1.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.17
  • P/E Growth: 0.0000
  • Market Cap: $101.15M
  • Outstanding Shares: 242,381,000
  • Beta: 1.14
Profitability:
  • Net Margins: -130.44%
  • Return on Equity: -96.28%
  • Return on Assets: -47.49%
Debt:
  • Current Ratio: 1.24%
  • Quick Ratio: 0.84%
Additional Links:
Companies Related to Peregrine Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $1.00 (139.64% upside)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetDetails
9/13/2016Roth CapitalReiterated RatingNeutral$0.50View Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$1.00View Rating Details
7/18/2016Noble FinancialReiterated RatingBuy$1.50View Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$3.50View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/8/2016        
9/8/2016Q1($0.04)($0.05)$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.03)($0.05)$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.07)($0.08)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.09)($0.07)$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.08)($0.08)$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.08)($0.07)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.08)($0.08)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.07)($0.07)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.06)($0.08)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.07)($0.06)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.06)($0.06)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.05)($0.05)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.05)($0.05)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.06)($0.06)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.07)($0.04)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.09)($0.08)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.11)($0.07)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.13)($0.10)ViewN/AView Earnings Details
3/9/2012($0.13)($0.13)ViewN/AView Earnings Details
12/12/2011($0.13)($0.16)ViewN/AView Earnings Details
9/9/2011($0.14)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Current Year EPS Consensus Estimate: $-0.1200 EPS
Next Year EPS Consensus Estimate: $-0.1000 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.05)($0.05)($0.05)
Q4 20161($0.05)($0.05)($0.05)
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateHeadline
capitalcube.com logoPeregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2017 By the Numbers : September 26, 2016 (NASDAQ:PPHM)
www.capitalcube.com - September 26 at 11:42 AM
News IconKeen Investors Find News on Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Duncan Research (NASDAQ:PPHM)
www.duncanindependent.com - September 23 at 6:21 PM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Provides Update ... - Scibility Media (NASDAQ:PPHM)
scibilitymedia.com - September 23 at 6:21 PM
capitalcube.com logoETF’s with exposure to Peregrine Pharmaceuticals, Inc. : September 23, 2016 (NASDAQ:PPHM)
www.capitalcube.com - September 23 at 11:35 AM
News IconUnder the Microscope, Zeroing in at Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Duncan Research (NASDAQ:PPHM)
www.duncanindependent.com - September 22 at 6:31 PM
News IconUnusual Biotech Volume Gainers in Focus- Peregrine Pharmaceuticals (PPHM), Northwest Biotherapeutics (NWBO) - Seneca Globe (NASDAQ:PPHM)
www.senecaglobe.com - September 22 at 6:31 PM
streetinsider.com logoPeregrine Pharma (PPHM) Will Present Topline Data from Bavituximab Phase 3 in NSCLC at ESMO 2016 (NASDAQ:PPHM)
www.streetinsider.com - September 22 at 11:40 AM
4-traders.com logoPeregrine Pharmaceuticals : PPHM, PPHMP) Issues Update on Presentation of Top-Line Data at European Society for Medical Oncology (NASDAQ:PPHM)
www.4-traders.com - September 22 at 11:40 AM
nasdaq.com logoPeregrine Pharmaceuticals Provides Update on Oral Presentation of (NASDAQ:PPHM)
www.nasdaq.com - September 22 at 11:40 AM
streetinsider.com logoPeregrine Pharma (PPHM) Will Present Topline Data from ... - StreetInsider.com (NASDAQ:PPHM)
www.streetinsider.com - September 21 at 10:53 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress (NASDAQ:PPHM)
finance.yahoo.com - September 21 at 10:53 AM
investornewswire.com logoShares Of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Expected To Hit $1.5 - Investor Newswire (NASDAQ:PPHM)
www.investornewswire.com - September 19 at 6:46 PM
News IconPeregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) To Report ... - The Voice Registrar (NASDAQ:PPHM)
voiceregistrar.com - September 17 at 11:17 AM
News IconKeen Investors Narrowing Their Focus on Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Duncan Research (NASDAQ:PPHM)
www.duncanindependent.com - September 15 at 10:24 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ: PPHM) Neutral Rating Reiterated at Roth Capital - BNB Daily (blog) (NASDAQ:PPHM)
www.baseball-news-blog.com - September 14 at 11:10 AM
investopedia.com logoPeregrine Results Reaffirm On-Track Revenue Projection (PPHM) (NASDAQ:PPHM)
www.investopedia.com - September 10 at 11:03 AM
News IconPeregrine Pharmaceuticals (NASDAQ:PPHM) just Keeps Getting Stronger (NASDAQ:PPHM)
streetregister.com - September 9 at 6:30 PM
News IconPeregrine Reports Financial Results For First Quarter Of Fiscal Year 2017 And Recent Developments (NASDAQ:PPHM)
www.biospace.com - September 9 at 6:30 PM
thestreet.com logoPeregrine Pharmaceuticals Reports Financial Results For First Quarter Of Fiscal Year 2017 And Recent Developments (NASDAQ:PPHM)
www.thestreet.com - September 8 at 6:34 PM
sg.finance.yahoo.com logoPeregrine reports 1Q loss (NASDAQ:PPHM)
sg.finance.yahoo.com - September 8 at 6:34 PM
biz.yahoo.com logoQ1 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:PPHM)
biz.yahoo.com - September 8 at 10:40 AM
News Icon$MSTX & $PPHM - Mast Therapeutics Inc (NYSEMKT:MSTX) & Peregrine Pharmaceuticals (NASDAQ:PPHM) Traders ... - Money News (NASDAQ:PPHM)
www.newsismoney.com - September 7 at 10:24 AM
News IconTrading the Biotech News: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), Ariad Pharmaceuticals Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PPHM)
voiceregistrar.com - September 7 at 10:24 AM
News IconSell-side's Take on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Earnings - Frisco Fastball (NASDAQ:PPHM)
friscofastball.com - September 6 at 6:57 PM
smarteranalyst.com logoCompany Update (NASDAQ:PPHM): Peregrine Pharmaceuticals Awarded Three NCCN Grants for Combination ... - Smarter Analyst (NASDAQ:PPHM)
www.smarteranalyst.com - September 6 at 6:57 PM
News IconTwo Biotechnology Names Are Hot: Peregrine Pharmaceuticals, Inc. (PPHM), Amicus Therapeutics, Inc. (FOLD) - The Independent Republic (NASDAQ:PPHM)
theindependentrepublic.com - September 6 at 6:57 PM
News IconTrending Stocks Buzz: Lam Research Corporation (NASDAQ:LRCX), Peregrine Pharmaceuticals (NASDAQ:PPHM ... - NYSE Journal (press release) (NASDAQ:PPHM)
stockznews.com - September 6 at 6:57 PM
News IconTime To Put On The Watch List? - Mast Therapeutics, Inc. (NYSEMKT:MSTX), Peregrine Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:PPHM)
voiceregistrar.com - September 6 at 6:57 PM
publicnow.com logoPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock (NASDAQ:PPHM)
www.publicnow.com - September 6 at 6:57 PM
biz.yahoo.com logoPEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:PPHM)
biz.yahoo.com - September 6 at 6:57 PM
finance.yahoo.com logoNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple Cancers (NASDAQ:PPHM)
finance.yahoo.com - September 6 at 11:38 AM
finance.yahoo.com logo8:52 am Peregrine Pharma provides $2 mln grant through the NNCN to support research of bavituximab in combination with other therapeutics for the treatment of glioblastoma, head and neck cancer, and hepatocellular carcinoma (NASDAQ:PPHM)
finance.yahoo.com - September 6 at 11:38 AM
publicnow.com logoNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals' Bavituximab in Multiple Cancers (NASDAQ:PPHM)
www.publicnow.com - September 6 at 11:38 AM
News IconPeregrine Pharmaceuticals (NASDAQ:PPHM): Reinforcing Our Bias Ahead Of Earnings (NASDAQ:PPHM)
streetregister.com - September 4 at 10:52 AM
News IconShares Gapping Higher Pre-Market: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Post News (NASDAQ:PPHM)
www.kentuckypostnews.com - September 2 at 11:42 AM
News IconPeregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) To Report July ... - The Voice Registrar (NASDAQ:PPHM)
voiceregistrar.com - September 2 at 11:42 AM
finance.yahoo.com logoPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September … (NASDAQ:PPHM)
finance.yahoo.com - September 1 at 6:48 PM
publicnow.com logoPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016 (NASDAQ:PPHM)
www.publicnow.com - September 1 at 6:48 PM
investornewswire.com logoCan Shares Of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Get To $1.5? - Investor Newswire (NASDAQ:PPHM)
www.investornewswire.com - August 29 at 6:39 PM
capitalcube.com logoETF’s with exposure to Peregrine Pharmaceuticals, Inc. : August 29, 2016 (NASDAQ:PPHM)
www.capitalcube.com - August 29 at 6:39 PM
News IconHow These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics (NASDAQ:PPHM)
www.biomedreports.com - August 26 at 6:38 PM
4-traders.com logoCara Therapeutics : How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics (NASDAQ:PPHM)
www.4-traders.com - August 26 at 9:50 AM
News IconHow is the Crowd Rating Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)? - Post News (NASDAQ:PPHM)
www.kentuckypostnews.com - August 24 at 9:56 AM
investornewswire.com logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:PPHM)
www.investornewswire.com - August 23 at 7:00 PM
capitalcube.com logoETF’s with exposure to Peregrine Pharmaceuticals, Inc. : August 18, 2016 (NASDAQ:PPHM)
www.capitalcube.com - August 18 at 7:04 PM
News IconCrowd Sentiment & Analyst Review on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Post News (NASDAQ:PPHM)
www.kentuckypostnews.com - August 17 at 9:55 AM
stocksdaily.net logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Ratings in Focus - Stocks Daily (NASDAQ:PPHM)
www.stocksdaily.net - August 16 at 10:09 AM
investornewswire.com logoWill Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Hit $1.5 Price Target? - Investor Newswire (NASDAQ:PPHM)
www.investornewswire.com - August 16 at 10:09 AM
realistinvestor.com logoAnalysts See Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Reporting EPS Of $-0.02 - RealistInvestor.com (NASDAQ:PPHM)
www.realistinvestor.com - August 16 at 10:09 AM
News IconTop Earnings to Watch for: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - The Voice Registrar (NASDAQ:PPHM)
voiceregistrar.com - August 9 at 7:10 PM

Social

Peregrine Pharmaceuticals (NASDAQ:PPHM) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff